Our results showed that these two components could suppress the release of IL-1β and TNF-α and the expression of NLRP3 and caspase-1 p20, similar to the effect of PEL, indicating that they were the active ingredients of LF in the treatment of RA. Here, NLRP3 is linked to rheumatoid arthritis.